- Home
- HUYA vs SGP Comparison
HUYA vs SGP Comparison
Compare HUYA & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HUYA | SGP |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 572.2M | 650.9M |
| IPO Year | 2018 | 2026 |
Fundamental Metrics
Financial Performance| Metric | HUYA | SGP |
|---|---|---|
| Price | $2.33 | $25.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $3.50 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 418.7K | 76.7K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | ★ 81.37% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.08 | N/A |
| Revenue Next Year | $6.11 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.15 | $17.06 |
| 52 Week High | $4.93 | $30.56 |
Technical Indicators
Market Signals| Indicator | HUYA | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 40.70 | 67.83 |
| Support Level | $2.15 | $20.95 |
| Resistance Level | $2.53 | $25.83 |
| Average True Range (ATR) | 0.09 | 1.32 |
| MACD | -0.01 | 0.26 |
| Stochastic Oscillator | 3.77 | 85.91 |
Price Performance
Historical ComparisonAbout HUYA HUYA Inc. American depositary shares each representing one ordinary share
Huya officially became independent in 2016 and is headquartered in Guangzhou. It operates a live streaming platform focused on games, esports, and interactive entertainment, and also provides game-related services such as distribution and in-game item sales. Its main livestreaming platforms include Huya Live in China and Nimo TV outside of China. Huya is a subsidiary of Tencent, which owned 67% of its equity stake and held 95% of the voting power, as of the end of 2025.
About SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.